Developing an Enterprise Roadmap to Post Authorization Safety Studies
Learn how an organization achieved organization-wide compliance and managed its post-authorization safety studies.
Top Barriers to Participation in Clinical Trials
Understanding the factors that influence the decision to participate in a study helps research professionals diagnose enrollment problems.
Return of Research Results to Study Participants
Research into participant experiences has consistently shown their desire to learn the results of research to which they’ve contributed.
Common Pitfalls in Preparing an IND Application
While the IND application process may be straightforward to some, we explore the most common pitfalls as sponsors prepare for submission.
IRB Review of Decentralized Trial Technology
Explore the current regulatory landscape governing mHealth and virtual trial applications in clinical research.
Patient Recruitment and Enrollment in Clinical Trials
Learn more about patient recruitment and enrollment: how they find out about clinical trials and the reasons they participate.
Four Questions to Ask When Establishing a Pharmacovigilance Organization
Four common but critical questions for emerging biotech organizations establishing a pharmacovigilance (PV) organization.
A Checklist for Optimizing Clinical Trial Study Startup Activities
This checklist outlines key milestones and considerations for sites and sponsors in the clinical trial study startup process.
Best Practices in Pre-Screening Includes Use of Technology
Explore the benefits of pre-screening potential participants before they move on to the informed consent process.
Common Elements of IRB Assessments
Like other IRBs, Advarra is subject to inspections from time to time. What standards are we measured against?
How Sites Want to be Engaged
Explore research programs' case studies where engagement strategies increased recruitment, reduced deviations, and achieved enrollment goals
Why do Funding and Legal Structure Matter in Decentralized Clinical Trials?
Both sites and sponsors must consider how DCT funding and legal structures can impact sites and the study itself.